Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer

Kiyotaka Yoh,Takashi Seto,Miyako Satouchi,Makoto Nishio,Noboru Yamamoto,Haruyasu Murakami,Naoyuki Nogami,Kaname Nosaki,Takashi Kohno,Koji Tsuta,Shogo Nomura,Takashi Ikeno,Masashi Wakabayashi,Akihiro Sato,Shingo Matsumoto,Koichi Goto

Lung Cancer（2021）

引用 17|浏览2

暂无评分

摘要

•RET fusion is a key oncogenic alteration in non-small cell lung cancer.•Vandetanib is an oral multikinase inhibitors with RET kinase activity.•Vandetanib has a clinically meaningful efficacy for RET-rearranged lung cancer.•Multikinase inhibitors lead to off-target adverse events not related to RET.•RET-selective inhibitors have improved efficacy and favorable toxicity profile.

查看译文

关键词

RET,Non-small cell lung cancer,Vandetanib,Phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要